title: Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies.
abstract: In the last decade several therapeutic antibodies have been Federal Drug Administration (FDA) and European Medicines Agency (EMEA) approved. Although their mechanisms of action in vivo is not fully elucidated, antibody-dependent cellular cytotoxicity (ADCC) mediated by natural killer (NK) cells is presumed to be a key effector function. A substantial role of ADCC has been demonstrated in vitro and in mouse tumor models. However, a direct in vivo effect of ADCC in tumor reactivity in humans remains to be shown. Several studies revealed a predictive value of FcγRIIIa-V158F polymorphism in monoclonal antibody treatment, indicating a potential effect of ADCC on outcome for certain indications. Furthermore, the use of therapeutic antibodies after allogeneic hematopoietic stem cell transplantation is an interesting option. Studying the role of the FcγRIIIa-V158F polymorphism and the influence of Killer-cell Immunoglobuline-like Receptor (KIR) receptor ligand incompatibility on ADCC in this approach may contribute to future transplantation strategies. Despite the success of approved second-generation antibodies in the treatment of several malignancies, efforts are made to further augment ADCC in vivo by antibody engineering. Here, we review currently used therapeutic antibodies for which ADCC has been suggested as effector function.
authors.affiliation: Department of General Paediatrics, Oncology/Haematology, University Children's Hospital Tübingen Tübingen, Germany.
authors.forename: Ursula J E
authors.initials: UJ
authors.lastname: Seidel
authors.forename: Patrick
authors.initials: P
authors.lastname: Schlegel
authors.forename: Peter
authors.initials: P
authors.lastname: Lang
keywords: ADCC; allogeneic stem cell transplantation; natural killer cells; therapeutic antibodies; tumor immunotherapy
references.citation: J Clin Oncol. 2008 Apr 10;26(11):1789-96
references.pmid: 18347005
references.citation: Pathol Oncol Res. 2012 Jan;18(1):43-8
references.pmid: 21667346
references.citation: Blood. 2011 Sep 22;118(12):3347-9
references.pmid: 21768303
references.citation: Pain. 2010 Apr;149(1):135-142
references.pmid: 20171010
references.citation: Nat Immunol. 2008 May;9(5):495-502
references.pmid: 18425106
references.citation: Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):728-32
references.pmid: 21187373
references.citation: Lancet. 2000 Nov 25;356(9244):1795-9
references.pmid: 11117911
references.citation: Eur J Cancer. 2012 Aug;48(12):1774-80
references.pmid: 22305465
references.citation: Leukemia. 2006 Feb;20(2):272-9
references.pmid: 16341049
references.citation: J Clin Oncol. 2007 Aug 20;25(24):3712-8
references.pmid: 17704420
references.citation: J Clin Invest. 2012 Sep;122(9):3260-70
references.pmid: 22863621
references.citation: Nat Med. 2000 Apr;6(4):443-6
references.pmid: 10742152
references.citation: J Biomed Biotechnol. 2011;2011:379123
references.pmid: 21660134
references.citation: Cancer Res. 2011 Aug 15;71(16):5412-22
references.pmid: 21708957
references.citation: J Mol Med (Berl). 2012 Jan;90(1):55-66
references.pmid: 21870102
references.citation: Br J Haematol. 2011 Oct;155(1):14-29
references.pmid: 21812770
references.citation: Cancer Res. 2007 Sep 15;67(18):8882-90
references.pmid: 17875730
references.citation: Leuk Lymphoma. 2010 Jul;51(7):1293-304
references.pmid: 20377308
references.citation: Leukemia. 2013 Jul;27(7):1595-8
references.pmid: 23277329
references.citation: J Clin Oncol. 2009 Mar 1;27(7):1122-9
references.pmid: 19164213
references.citation: J Clin Oncol. 2008 Nov 20;26(33):5489-91; author reply 5491-2
references.pmid: 18955438
references.citation: Blood. 1997 Aug 1;90(3):1109-14
references.pmid: 9242542
references.citation: Int J Cancer. 1975 Aug 15;16(2):230-9
references.pmid: 1080480
references.citation: Science. 2011 Jan 7;331(6013):44-9
references.pmid: 21212348
references.citation: Clin Cancer Res. 2012 Jun 15;18(12):3478-86
references.pmid: 22504044
references.citation: J Clin Invest. 1997 Sep 1;100(5):1059-70
references.pmid: 9276722
references.citation: Cancer Res. 2010 Dec 1;70(23):9554-61
references.pmid: 20935224
references.citation: J Exp Med. 2009 Jul 6;206(7):1495-503
references.pmid: 19528259
references.citation: Blood. 2005 Jan 1;105(1):289-91
references.pmid: 15217834
references.citation: Curr Hematol Malig Rep. 2010 Jul;5(3):140-7
references.pmid: 20446121
references.citation: J Clin Oncol. 2003 Nov 1;21(21):3940-7
references.pmid: 12975461
references.citation: BMC Cancer. 2011 Nov 25;11:496
references.pmid: 22117530
references.citation: Blood. 2006 Jan 1;107(1):159-66
references.pmid: 16150947
references.citation: Br J Haematol. 2011 Nov;155(4):426-37
references.pmid: 21902688
references.citation: Nat Rev Immunol. 2008 Jan;8(1):34-47
references.pmid: 18064051
references.citation: J Immunol. 1973 Dec;111(6):862-71
references.pmid: 4750872
references.citation: Cancer Res. 2008 Feb 15;68(4):976-80
references.pmid: 18281470
references.citation: Trends Immunol. 2005 Apr;26(4):221-6
references.pmid: 15797513
references.citation: Curr Opin Immunol. 2007 Jun;19(3):365-72
references.pmid: 17442558
references.citation: Blood. 2006 Oct 15;108(8):2720-5
references.pmid: 16609067
references.citation: Blood. 2002 Feb 1;99(3):754-8
references.pmid: 11806974
references.citation: Glycobiology. 1995 Dec;5(8):813-22
references.pmid: 8720080
references.citation: Clin Cancer Res. 2009 Dec 1;15(23):7330-4
references.pmid: 19934297
references.citation: Cancer Res. 2004 Jul 1;64(13):4664-9
references.pmid: 15231679
references.citation: Nat Biotechnol. 1999 Feb;17(2):176-80
references.pmid: 10052355
references.citation: BMC Cancer. 2011 Jan 18;11:21
references.pmid: 21244693
references.citation: Haematologica. 2007 Jul;92(7):998-9
references.pmid: 17606457
references.citation: Curr Cancer Drug Targets. 2010 Mar;10(2):200-9
references.pmid: 20201786
references.citation: Immunology. 2009 Oct;128(2):260-70
references.pmid: 19740383
references.citation: Clin Cancer Res. 2012 Nov 15;18(22):6296-305
references.pmid: 23014531
references.citation: Biotechnol Bioeng. 2001 Aug 20;74(4):288-94
references.pmid: 11410853
references.citation: Leukemia. 2011 Jan;25(1):101-9
references.pmid: 20975664
references.citation: Proc Natl Acad Sci U S A. 2006 Mar 14;103(11):4005-10
references.pmid: 16537476
references.citation: Cancer Res. 2005 Nov 15;65(22):10562-8
references.pmid: 16288049
references.citation: Leukemia. 2012 Jun;26(6):1228-37
references.pmid: 22289926
references.citation: J Immunol. 1986 Jun 15;136(12):4480-6
references.pmid: 3086432
references.citation: Blood. 2010 Nov 18;116(20):4212-22
references.pmid: 20705761
references.citation: Int J Cancer. 1975 Aug 15;16(2):216-29
references.pmid: 50294
references.citation: J Clin Oncol. 2010 Nov 20;28(33):4969-75
references.pmid: 20921469
references.citation: Eur J Immunol. 1975 Feb;5(2):117-21
references.pmid: 1086218
references.citation: J Immunol. 2011 Dec 1;187(11):5693-702
references.pmid: 22021614
references.citation: Curr Opin Immunol. 2003 Jun;15(3):308-14
references.pmid: 12787756
references.citation: AIDS Res Hum Retroviruses. 2002 Nov 1;18(16):1197-205
references.pmid: 12487826
references.citation: J Biol Chem. 2001 Mar 2;276(9):6591-604
references.pmid: 11096108
references.citation: N Engl J Med. 2007 Jul 5;357(1):39-51
references.pmid: 17611206
references.citation: Curr Opin Hematol. 2012 Jul;19(4):319-23
references.pmid: 22555394
references.citation: Cancer Res. 2011 Aug 1;71(15):5134-43
references.pmid: 21697279
references.citation: N Engl J Med. 2009 Apr 2;360(14):1408-17
references.pmid: 19339720
references.citation: J Biol Chem. 2003 Jan 31;278(5):3466-73
references.pmid: 12427744
references.citation: Immunol Rev. 1995 Aug;146:211-21
references.pmid: 7493755
references.citation: N Engl J Med. 2008 Aug 7;359(6):613-26
references.pmid: 18687642
references.citation: Blood. 2010 Feb 11;115(6):1204-13
references.pmid: 19965644
references.citation: Blood. 2004 May 15;103(10):3982-5
references.pmid: 14764538
references.citation: Ann Oncol. 2005 Oct;16(10):1675-82
references.pmid: 16030029
references.citation: J Immunother. 2006 Mar-Apr;29(2):122-33
references.pmid: 16531813
references.citation: Clin Cancer Res. 2012 Mar 1;18(5):1395-403
references.pmid: 22223529
references.citation: Clin Exp Immunol. 1992 Jan;87(1):105-10
references.pmid: 1339322
references.citation: Cancer. 2008 Feb 15;112(4):863-75
references.pmid: 18203207
references.citation: Nat Rev Cancer. 2012 Mar 22;12(4):278-87
references.pmid: 22437872
references.citation: Curr Opin Immunol. 2008 Jun;20(3):344-52
references.pmid: 18439809
references.citation: N Engl J Med. 2010 Sep 30;363(14):1324-34
references.pmid: 20879881
references.citation: Neoplasma. 2011;58(3):263-70
references.pmid: 21395368
references.citation: Semin Immunol. 2006 Jun;18(3):151-8
references.pmid: 16730454
references.citation: Annu Rev Immunol. 2001;19:197-223
references.pmid: 11244035
references.citation: Clin Cancer Res. 2011 Feb 15;17(4):678-89
references.pmid: 21325295
references.citation: Eur J Cancer. 1995;31A(2):261-7
references.pmid: 7718335
references.citation: Oncology. 2012;82(2):83-9
references.pmid: 22327884
references.citation: J Clin Oncol. 2011 Oct 1;29(28):3783-90
references.pmid: 21900113
references.citation: Blood. 2006 Oct 15;108(8):2648-54
references.pmid: 16825493
references.citation: Blood. 2011 Mar 17;117(11):2993-3001
references.pmid: 21209380
references.citation: Int J Cancer. 1972 May 15;9(3):648-58
references.pmid: 4513057
references.citation: J Clin Oncol. 2007 Dec 10;25(35):5616-23
references.pmid: 17984186
references.citation: Curr Opin Investig Drugs. 2009 Jun;10(6):588-96
references.pmid: 19513948
references.citation: Breast Cancer Res. 2011;13(6):R123
references.pmid: 22129105
references.citation: Ann Oncol. 2011 Jun;22(6):1302-1307
references.pmid: 21109570
references.citation: Eur J Immunol. 1975 Feb;5(2):112-7
references.pmid: 1234049
references.citation: Blood. 2010 Oct 21;116(16):3004-12
references.pmid: 20616215
references.citation: Haematologica. 2007 Aug;92(8):1127-30
references.pmid: 17650444
references.citation: MAbs. 2012 Jul-Aug;4(4):419-25
references.pmid: 22699226